Key facts
- It has raised $214.6M across 7 recorded rounds; the latest was Later Stage VC (Series B) ($115.0M) in Feb 2026.
- Notable investors include RA Capital Management, National Institutes of Health, European Union, BNP Paribas Asset Management, Knott Partners Management — 11 tracked in total.
- ILiAD Biotechnologies has filed 11 Form Ds with the SEC since 2017, most recently Feb 2026 ($115.5M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for ILiAD Biotechnologies
Funding rounds
7 roundsAbout ILiAD Biotechnologies
Developer of a medical vaccine designed to prevent and offer treatment for human disease caused by Bordetella pertussis. The company's vaccine specializes in attenuated pertussis, inducing the immune system to produce protective antibodies to eradicate the infection, enabling patients to recover from whooping cough and other serious diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Weston, FL, United States
- Founded
- 2012
- Employees
- 25
- Website
- iliadbio.com/
- Ownership
- Privately Held (backing)
ILiAD Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ILiAD Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ILiAD Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.